{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:06:22Z","timestamp":1790676382902,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Existing research indicates that patients with heart failure (HF) may have restricted access to guideline-directed medical therapy (GDMT) when their blood pressure (BP) is comparatively low. However, recent clinical trials suggest that HF patients with low BP could still benefit from certain HF medications, which have a minimal impact on BP. This systematic review and meta-analysis was conducted to determine whether this applies to all GDMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE and EMBASE was conducted for studies published from inception to 10 January 2024. Randomized controlled trials were selected if they reported on the longitudinal change of systolic BP (SBP) due to GDMT, or the risks of cardiovascular events in HF patients based on SBP categories. Weighted mean difference (WMD), hazard ratio or relative risk, and corresponding 95% confidence intervals (CI) were pooled for meta-analysis where possible. Data from 20 studies, encompassing information on 84\u2009782 individuals, were analysed. Overall, GDMT is associated with lower SBP (WMD, \u22122.16; 95% CI \u22122.86 to \u22121.46), with no significant difference between baseline low and non-low BP subgroups (interaction p\u2009=\u20090.810). However, SBP of the treatment group increased by 5.8\u2009mmHg from baseline in the low SBP subgroup during follow-up, while it decreased by 4.0\u2009mmHg in the baseline non-low SBP subgroup. GDMT demonstrated similar cardiovascular benefits and risk of hypotension between low and non-low SBP subgroups (interaction p =\u20090.318 and 0.903, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Guideline-directed medical therapy is associated with a negligible decrease in SBP, but can provide similar cardiovascular benefits in both low and non-low SBP HF patients, with no significant interaction with SBP as to hypotension. Therefore, GDMT should be initiated and maintained in HF patients with low BP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3208","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T05:10:44Z","timestamp":1712898644000},"page":"1435-1442","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Guideline-Directed Medical Therapy on Systolic Blood Pressure and Cardiovascular Outcomes in Patients with Heart Failure and Low Blood Pressure: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"26","author":[{"given":"Jingwei","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]},{"name":"The George Institute for Global Health, Faculty of Medicine, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Xinqiao Hospital, Army Military Medical University , Chongqing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Anderson","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, Faculty of Medicine, University of New South Wales , Sydney, NSW ,","place":["Australia"]},{"name":"Department of Neurology, Royal Prince Alfred Hospital, The University of Sydney , Sydney, NSW ,","place":["Australia"]},{"name":"Faculty of Medicine Clinica Alemana Universidad del Desarrollo , Santiago ,","place":["Chile"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"2026010913061421500_ejhf3208-bib-0001","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0002","doi-asserted-by":"crossref","first-page":"D50","DOI":"10.1093\/ehjsupp\/4.suppl_D.D50","article-title":"The burden of heart failure","volume":"4","author":"McMurray","year":"2002","journal-title":"Eur Heart J Suppl"},{"key":"2026010913061421500_ejhf3208-bib-0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5152\/akd.2014.5731","article-title":"Mortality in heart failure patients","volume":"15","author":"Byty\u00e7i","year":"2015","journal-title":"Anatol J Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ahj.2010.12.009","article-title":"Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship","volume":"161","author":"Ather","year":"2011","journal-title":"Am Heart J"},{"key":"2026010913061421500_ejhf3208-bib-0005","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/ejhf.1835","article-title":"Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients","volume":"22","author":"Cautela","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0006","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2026010913061421500_ejhf3208-bib-0007","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jchf.2022.09.002","article-title":"Blood pressure and dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: DELIVER","volume":"11","author":"Selvaraj","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0008","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.jacc.2008.09.011","article-title":"Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program","volume":"52","author":"Meredith","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0009","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.jacc.2003.11.037","article-title":"Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"43","author":"Rouleau","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0010","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1097\/HJH.0000000000002116","article-title":"Sex differences in blood pressure after stroke: A systematic review and meta-analysis","volume":"37","author":"Li","year":"2019","journal-title":"J Hypertens"},{"key":"2026010913061421500_ejhf3208-bib-0011","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/eurheartj\/ehi386","article-title":"Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: Results from the COMET trial","volume":"26","author":"Metra","year":"2005","journal-title":"Eur Heart J"},{"key":"2026010913061421500_ejhf3208-bib-0012","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010913061421500_ejhf3208-bib-0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.pcad.2020.04.008","article-title":"The impact of 2019 novel coronavirus on heart injury: A systematic review and meta-analysis","volume":"63","author":"Li","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"2026010913061421500_ejhf3208-bib-0014","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/eurheartj\/ehac693","article-title":"Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: The EMPEROR-Preserved trial","volume":"44","author":"B\u00f6hm","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010913061421500_ejhf3208-bib-0015","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0016","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","article-title":"Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: The GALACTIC-HF trial","volume":"43","author":"Metra","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913061421500_ejhf3208-bib-0017","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCHEARTFAILURE.107.736975","article-title":"Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial","volume":"1","author":"Anand","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0018","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jchf.2019.09.011","article-title":"Mineralocorticoid receptor antagonists, blood pressure, and outcomes in heart failure with reduced ejection fraction","volume":"8","author":"Serenelli","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0019","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1093\/eurheartj\/ehaa496","article-title":"Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)","volume":"41","author":"Serenelli","year":"2020","journal-title":"Eur Heart J"},{"key":"2026010913061421500_ejhf3208-bib-0020","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jacc.2021.07.049","article-title":"Empagliflozin improves cardiovascular and renal outcomes in heart failure irrespective of systolic blood pressure","volume":"78","author":"B\u00f6hm","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.021094","article-title":"Blood pressure and safety events with vericiguat in the VICTORIA trial","volume":"10","author":"Lam","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026010913061421500_ejhf3208-bib-0022","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/ejhf.136","article-title":"Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: Data from the SENIORS trial","volume":"16","author":"Montero-Perez-Barquero","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0023","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: An analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0024","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/hc1002.105180","article-title":"Tolerability of beta-blocker initiation and titration in the Metoprolol CR\/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"2026010913061421500_ejhf3208-bib-0025","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ejhf.114","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT","volume":"16","author":"Komajda","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0026","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jacc.2006.04.109","article-title":"Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial","volume":"49","author":"Anand","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0027","first-page":"354","article-title":"Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: A prespecified post hoc analysis of BEST","volume":"28","author":"White","year":"2012","journal-title":"Can J Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0028","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"2026010913061421500_ejhf3208-bib-0029","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026010913061421500_ejhf3208-bib-0030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.tcm.2022.05.005","article-title":"SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure","volume":"33","author":"Gupta","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"2026010913061421500_ejhf3208-bib-0031","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jchf.2023.03.009","article-title":"Guideline-directed medical therapy tolerability in patients with heart failure and mitral regurgitation: The COAPT trial","volume":"11","author":"Cox","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0032","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026010913061421500_ejhf3208-bib-0033","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jchf.2018.11.011","article-title":"Target doses of heart failure medical therapy and blood pressure: Insights from the CHAMP-HF registry","volume":"7","author":"Peri-Okonny","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026010913061421500_ejhf3208-bib-0034","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00392-020-01790-y","article-title":"Guideline-directed medical therapy in real-world heart failure patients with low blood pressure and renal dysfunction","volume":"110","author":"Chen","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2022.10.129","article-title":"Low blood pressure and guideline-directed medical therapy in patients with heart failure with reduced ejection fraction","volume":"370","author":"Izumi","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026010913061421500_ejhf3208-bib-0036","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028750","article-title":"Development of hypotension in patients newly diagnosed with heart failure in UK general practice: Retrospective cohort and nested case-control analyses","volume":"9","author":"Mart\u00edn-P\u00e9rez","year":"2019","journal-title":"BMJ Open"},{"key":"2026010913061421500_ejhf3208-bib-0037","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J Hypertens"},{"key":"2026010913061421500_ejhf3208-bib-0038","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jchf.2022.10.005","article-title":"How to initiate and uptitrate GDMT in heart failure: Practical stepwise approach to optimization of GDMT","volume":"10","author":"Bozkurt","year":"2022","journal-title":"JACC Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/6\/1435\/65512623\/eurjhf_26_6_1435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/6\/1435\/65512623\/eurjhf_26_6_1435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:07:39Z","timestamp":1767982059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/6\/1435\/8328744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3208","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"2024-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}